PIK3CA and breast carcinoma: Therefore, although adding inavolisib to palbociclib and fulvestrant provides additional survival benefits for patients with PIK3CA-mutated advanced breast cancer, its high cost raises concerns regarding its economic value and accessibility across different healthcare systems.